New hope for tough lung cancers: experimental drug targets immunotherapy failures

NCT ID NCT07133425

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether the experimental drug SAR445877 can help control advanced non-small cell lung cancer in people whose tumors no longer respond to immunotherapy. About 29 adults with locally advanced or metastatic disease will receive the drug by IV. The main goal is to check safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR445877 (given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer whose tumors no longer respond to standard immunotherapy.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply widely. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICI-REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICI-REFRACTORY NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.